ALSO NOTED: Jarvik takes fourth in ad ranking;Glaxo slashes AIDS drug costs for poor;

> Which TV drug ads lodged most securely in consumers' brains? That ubiquitous Nasonex bee hit No. 1, with Rozerem's talking animal coming in second. The Vytorin ads--pulled in the wake of the controversial Enhance trial--took third place, while the also-controversial Lipitor campaign featuring Robert Jarvik came in fourth. Report | Ranking

> Some biotechs are eager for the FDA approval of biogeneric drugs. Report

> A Nevada judge knocked down a $134 million jury award to three women who blamed Wyeth's hormone therapies for their breast cancer; the new figure is about $58 million. The company still faces some 5,000 similar lawsuits across the country. Report

> GlaxoSmithKline cut the cost of its AIDS drugs for patients in the world's poorest countries; one drug often used in children was discounted 40 percent. Report

> Covering the cost of drugs for people who have heart attacks would lengthen lives and lower medical costs, new research shows. Report

> Thailand's plan to review its compulsory licensing of four cancer drugs hit a big obstacle when three government ministers found that it cannot be revoked. Report

> Watson Pharmaceutical posted fourth-quarter profits of $38.4 million, a big swing upward from last year's loss of $489 million on acquisition and R&D charges. Sales grew slightly to $627.3 million. Release | Report

> India's Sun Pharmaceutical increased its stake in Israel-based Taro Pharmaceutical industries to 34.4 percent. Report

> Moody's upped its rating on Merck KGaA to "positive" from "stable," citing the German company's rapid de-leveraging. Report

> IDM Pharma said it had met minimum bid price requirements to regain compliance with Nasdaq Stock Market rules. Report

> A new survey has concluded that specialists feel Medicare's new anemia drug payment limits are hurting cancer patients. Report

> Do the psychiatric symptoms seen in some Chantix patients say more about cigarettes than about the drug? Report

And Finally... Here's a new business model for biotechnology: Pet cloning. South Korea's RNL Bio says it has its first $50,000 order to clone a dog from the biologic material remaining from a California woman's pet bull terrier. Report

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.